Navigation Links
Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Date:1/3/2008

ANA598 demonstrates significant antiviral activity in vivo

SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced preliminary data today from two studies of ANA598, a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, in a primate model of chronic HCV infection.

Two animals chronically infected with HCV genotype 1b each received once-daily oral doses of ANA598 at 30 mg/kg for four days. A rapid viral load decline was seen in both animals. At 48 hours (24 hours after the second dose), viral load declines were 2.2 and 2.6 log10 in the individual animals. In one animal the viral load reduction was sustained throughout the remaining dosing period, while in the second animal a modest rise in viral load was seen over days 3 and 4, although the rise observed (0.6 log10) was within the baseline variability seen in this animal prior to dosing.

In a previous study conducted to assess the pharmacokinetics (PK), safety, tolerability and preliminary antiviral activity of ANA598, two HCV genotype 1a infected animals received a single oral dose of ANA598 at 30 mg/kg. At 24 hours after dosing, plasma levels of ANA598 exceeded the replicon EC95 values. At 48 hours after dosing, the mean viral load decline in the two animals was 1.0 log10. ANA598 was well tolerated by all of the animals in both studies.

"These positive animal efficacy data reinforce our continued enthusiasm for development of ANA598 as a potential new direct antiviral treatment for chronic HCV," said Steve Worland, Ph.D., President and Chief Executive Officer of Anadys. "The rapid viral load decline and the favorable PK, safety and tolerability profile demonstrated in these animal efficacy stu
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
4. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
7. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., , CHICAGO and STAFA, Switzerland, Nov. 25... leading manufacturer of innovative hearing soluti...are for Adults Conference, focusing on the special...ught together leading experts in aging and audiolo...ans who work everyday with older people with heari...
(Date:11/25/2009)..., , BRIDGEWATER, N.J., Nov. 25 /PRNewswire/ ...NCE® (etravirine) tablets, a non-nucleoside r...is the only NNRTI specifically indicated for use i...g virologic failure with HIV-1 strains resistant t... The traditional approval is based on 48-week data...
(Date:11/25/2009)..., , COLLEGE PARK, Md., Nov. 25 /PRNewswir...pany developing a shaving cream-like foam that sto... the Most Promising Security Idea category of the ...announce today. ,, Selected from more than 100 ...ched their invention at the GSC Security Summit co...
Breaking Medicine Technology:Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Pregis Announces Third Quarter 2009 Financial Results 61271 1Pregis Announces Third Quarter 2009 Financial Results 61271 2Pregis Announces Third Quarter 2009 Financial Results 61271 3Pregis Announces Third Quarter 2009 Financial Results 61271 4Pregis Announces Third Quarter 2009 Financial Results 61271 5Pregis Announces Third Quarter 2009 Financial Results 61271 6Pregis Announces Third Quarter 2009 Financial Results 61271 7Pregis Announces Third Quarter 2009 Financial Results 61271 8Pregis Announces Third Quarter 2009 Financial Results 61271 9Pregis Announces Third Quarter 2009 Financial Results 61271 10Pregis Announces Third Quarter 2009 Financial Results 61271 11Pregis Announces Third Quarter 2009 Financial Results 61271 12Pregis Announces Third Quarter 2009 Financial Results 61271 13Pregis Announces Third Quarter 2009 Financial Results 61271 14Pregis Announces Third Quarter 2009 Financial Results 61271 15Pregis Announces Third Quarter 2009 Financial Results 61271 16Bioniche Pharma Acquires Duraclon 28R 29 28clonidine hydrochloride injection 29 and Methadone Hydrochloride Injection USP 61269 1Bioniche Pharma Acquires Duraclon 28R 29 28clonidine hydrochloride injection 29 and Methadone Hydrochloride Injection USP 61269 2AvidBiotics Corp Granted Key U S and European Patents on Unique Protein Modification Platform 14820 1AvidBiotics Corp Granted Key U S and European Patents on Unique Protein Modification Platform 14820 2
... Oct. 25 BiPar Sciences, Inc., a,privately held b...herapies,today announced molecular biomarker data ...-ADP-ribose polymerase) protein in multiple cancer...esearch is the first,demonstration of PARP overexp...is being used to guide the clinical development of...
...chnology identifies small molecule JAK2 and Pim ki...N FRANCISCO, Oct. 25 SuperGen Inc. (Nasdaq:,SUPG)...ery, rapid,development and commercialization of th...ncies, today announced data as part of a series of...ional Conference that,describe how its proprietary...
Other Medicine Technology:BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types 2Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization 2Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization 3
(Date:11/27/2009)...wire-USNewswire/ -- Considered a highly risky and ... solid organ transplantation is now a life-saving ...en and women who gathered at the Winspear Opera Ho...om medical centers around the world to celebrate t...Institute (BRTI), one of the pioneers of solid org...
(Date:11/27/2009)...7 Preventing disease is...ately every year, new vaccines are being added to ...boost immunity for the same period of time? And, i...to keep immunity strong? ,, In this month,s i...ademy of Pediatrics, Michael Pichichero MD, Direct...
(Date:11/27/2009)...Nov. 27 Shamir Optical I...ing provider of innovative products and technology...at its board of directors had declared a dividend ...ion (approximately NIS 37.62 million based on the ..., or approximately US$ 0.609 (approximately NIS 2....
(Date:11/27/2009)...on vehicles may reduce future disease burden, rese...ay News) -- Encouraging city dwellers to walk and ...ater public health benefits than increased used of...d. , The study compared the projected health ef...scenarios for London, England, and Delhi, India: ...
(Date:11/27/2009)..., Nov. 27 Allrecipes.com , the ...iving traffic numbers, with more than 2.8 million ...clear picture of what was served on the biggest fo...eal in 2009 weighed in at 2,225 calories per servi...ccording to the Allrecipes site, Sweet Potato Pie...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4
...n to sounds, might be way to spot hearing problems...hDay News) -- The eyes may not just be a window to...he state of your other senses. , A new study repor...blems in babies, very young children and in people...
...9 A new national study among,467 Americans reveal...,Pettitte when he testified that he had two conver...se of HGH and Roger Clemens use of steroids., (Lo....com web site, to obtain Americans, views on comme...
...e-aged women who suffered physical or sexual abuse...ge in health-care costs, according to a long-term ...ter the abuse ended, these women used health servi...0s still suffer consequences from abuse that occur...
...Persons exposed to radioactive fallout from the Ch...an increased risk of follicular adenoma or benign ...rs at Columbia University Mailman School of Public...is is the first epidemiologic study of the associa...
...arine Corps Casualty Assistance,Calls Officers (CA...ly,concerning the loss, injury or illness of their... to execute this critical duty by noted author and...arters Marine Corps Casualty,Conference in Quantic...
...Therapy Is an Effective Treatment of Choice for,Ma...In contrast to a,recent study published in the Jou...ggesting that spine-related expenditures have incr... and neck,pain, report good outcomes at a lower co...
Other Medicine News:Health News:Eyes a Window to Hearing Loss? 2Health News:Eyes a Window to Hearing Loss? 3Health News:Americans Believe Pettitte had Conversations with Clemens Regarding Both Players' Use of HGH 2Health News:Women who suffered child abuse spend more on health care 2Health News:Women who suffered child abuse spend more on health care 3Health News:Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl 2Health News:Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl 3Health News:Joanne Steen Presents Grief Solutions at the Headquarters Marine Corps 2008 Casualty Conference 2Health News:Physical Therapists Offer Low-Cost Solution to High-Cost Expenditures for Spinal Conditions 2Health News:Physical Therapists Offer Low-Cost Solution to High-Cost Expenditures for Spinal Conditions 3
Expander Sizer™
Mid-Thigh Girdle
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper
Short Girdle, High Waist, Mid-thigh
Medicine Products: